Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biopharmaceutical company Synergy Pharmaceuticals has appointed Melvin Spigelman as a director of the company.
Subscribe to our email newsletter
In addition, the board of directors appointed Dr Spigelman as chairman of the company’s clinical oversight committee as well as a member of the compensation committee.
Dr Spigelman has served as director of R&D for the Global Alliance for TB Drug Development. Dr Spigelman has received a BA in engineering from Brown University and an MD from The Mount Sinai School of Medicine, and is board certified in internal medicine, medical oncology and preventive medicine.
Gary Jacob, president and acting CEO of Synergy, said: “As chairman of Synergy’s clinical oversight committee, Mel will provide critical input to Synergy management on the clinical development of SP-304, Synergy’s drug that recently entered clinical trials to treat gastrointestinal disorders. We are pleased to have Mel join our board and fully expect that his unique experience will be a major asset to Synergy.”